Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
Abstract
..
All curcumin studies
..
Meta analysis
..
Feedback
Home
←
next
study
→
previous
study
c19early.org COVID-19 treatment researchCurcuminCurcumin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
All Studies   Meta Analysis       

Structure-based drug discovery to identify SARS-CoV2 spike protein–ACE2 interaction inhibitors

Kant et al., Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2023.2300060
Jan 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Curcumin for COVID-19
15th treatment shown to reduce risk in February 2021, now with p = 0.0000000096 from 27 studies.
Lower risk for mortality, ventilation, hospitalization, progression, recovery, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
In Silico study showing that curcumin strongly inhibits the interaction between the SARS-CoV-2 spike protein receptor binding domain (RBD) and the human ACE2 receptor for the delta and omicron variants. Molecular docking and dynamics simulations revealed curcumin's higher binding efficiency compared to other lead compounds, which may be due to spike protein mutations altering the RBD structure and ACE2 interactions.
51 preclinical studies support the efficacy of curcumin for COVID-19:
26 In Silico studies1-26
24 In Vitro studies1,3,7,9,13,19,23,27-43
1 In Vivo animal study7
In Silico studies predict inhibition of SARS-CoV-2 with curcumin or metabolites via binding to the spikeA,1,2,7,12,14,20,23 (and specifically the receptor binding domainB,10,13,16), MproC,1,2,7,9,11-13,15,16,18,21,23,24,26,40, RNA-dependent RNA polymeraseD,1,2,13,22, PLproE,2, ACE2F,14,15,17, nucleocapsidG,8,25, nsp10H,25, and helicaseI,29 proteins. In Vitro studies demonstrate inhibition of the spikeA,34 (and specifically the receptor binding domainB,43), MproC,19,34,40,42, ACE2F,43, and TMPRSS2J,43 proteins, and inhibition of spike-ACE2 interactionK,27. In Vitro studies demonstrate efficacy in Calu-3L,41, A549M,34, 293TN,3, HEK293-hACE2O,19,32, 293T/hACE2/TMPRSS2P,33, Vero E6Q,9,13,23,32,34,36,37,39,41, and SH-SY5YR,31 cells. Curcumin is predicted to inhibit the interaction between the SARS-CoV-2 spike protein receptor binding domain and the human ACE2 receptor for the delta and omicron variants10, decreases pro-inflammatory cytokines induced by SARS-CoV-2 in peripheral blood mononuclear cells39, alleviates SARS-CoV-2 spike protein-induced mitochondrial membrane damage and oxidative stress3, may limit COVID-19 induced cardiac damage by inhibiting the NF-κB signaling pathway which mediates the profibrotic effects of the SARS-CoV-2 spike protein on cardiac fibroblasts28, and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity35.
Important missing comments or errors? Let us know.
a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.
b. The receptor binding domain is a specific region of the spike protein that binds ACE2 and is a major target of neutralizing antibodies. Focusing on the precise binding site allows highly specific disruption of viral attachment with reduced potential for off-target effects.
c. The main protease or Mpro, also known as 3CLpro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting Mpro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.
d. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.
e. The papain-like protease (PLpro) has multiple functions including cleaving viral polyproteins and suppressing the host immune response by deubiquitination and deISGylation of host proteins. Inhibiting PLpro may block viral replication and help restore normal immune responses.
f. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.
g. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.
h. Non-structural protein 10 (nsp10) serves as an RNA chaperone and stabilizes conformations of nsp12 and nsp14 in the replicase-transcriptase complex, which synthesizes new viral RNAs. Nsp10 disruption may destabilize replicase-transcriptase complex activity.
i. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.
j. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.
k. The interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor is a primary method of viral entry, inhibiting this interaction can prevent the virus from attaching to and entering host cells, halting infection at an early stage.
l. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.
m. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.
n. 293T is a human embryonic kidney cell line that can be engineered for high ACE2 expression and SARS-CoV-2 susceptibility. 293T cells are easily transfected and support high protein expression.
o. HEK293-hACE2 is a human embryonic kidney cell line with high ACE2 expression and SARS-CoV-2 susceptibility. Cells have been transfected with a plasmid to express the human ACE2 (hACE2) protein.
p. 293T/hACE2/TMPRSS2 is a human embryonic kidney cell line engineered for high ACE2 and TMPRSS2 expression, which mimics key aspects of human infection. 293T/hACE2/TMPRSS2 cells are very susceptible to SARS-CoV-2 infection.
q. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.
r. SH-SY5Y is a human neuroblastoma cell line that exhibits neuronal phenotypes. It is commonly used as an in vitro model for studying neurotoxicity, neurodegenerative diseases, and neuronal differentiation.
Kant et al., 4 Jan 2024, peer-reviewed, 4 authors.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperCurcuminAll
{ 'indexed': {'date-parts': [[2024, 1, 5]], 'date-time': '2024-01-05T00:14:09Z', 'timestamp': 1704413649178}, 'reference-count': 66, 'publisher': 'Informa UK Limited', 'funder': [ { 'DOI': '10.13039/501100001411', 'name': 'Indian Council of Medical Research', 'doi-asserted-by': 'publisher'}, { 'DOI': '10.13039/501100010803', 'name': 'Department of Biotechnology', 'doi-asserted-by': 'publisher', 'award': ['BT/PR40153/BTIS/137/8/2021']}, { 'name': 'Ministry of Science and Technology, India, Indian Council of Medical Research', 'award': ['HIV/STI/17/02/2022-ECD-II']}], 'content-domain': {'domain': ['www.tandfonline.com'], 'crossmark-restriction': True}, 'DOI': '10.1080/07391102.2023.2300060', 'type': 'journal-article', 'created': {'date-parts': [[2024, 1, 4]], 'date-time': '2024-01-04T09:48:32Z', 'timestamp': 1704361712000}, 'page': '1-19', 'update-policy': 'http://dx.doi.org/10.1080/tandf_crossmark_01', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Structure-based drug discovery to identify SARS-CoV2 spike protein–ACE2 interaction inhibitors', 'prefix': '10.1080', 'author': [ { 'given': 'Ravi', 'family': 'Kant', 'sequence': 'first', 'affiliation': [ { 'name': 'Medical Biotechnology Laboratory, Dr. B. R. Ambedkar Center for ' 'Biomedical Research &amp;Delhi School of Public Health, IoE, ' 'University of Delhi, Delhi, India'}]}, { 'given': 'Rahul', 'family': 'Kaushik', 'sequence': 'additional', 'affiliation': [ { 'name': 'Biotechology Research Center, Technology Innovation Institute, ' 'Masdar City, UAE'}, { 'name': 'Laboratory for Structural Bioinformatics, Center for Biosystems ' 'Dynamics Research, RIKEN, Yokohama, Japan'}]}, { 'given': 'Madhu', 'family': 'Chopra', 'sequence': 'additional', 'affiliation': [ { 'name': 'Laboratory of Molecular Modeling and Drug Development, Dr. B. R. ' 'Ambedkar Center for Biomedical Research, University of Delhi, ' 'Delhi, India'}]}, { 'given': 'Daman', 'family': 'Saluja', 'sequence': 'additional', 'affiliation': [ { 'name': 'Medical Biotechnology Laboratory, Dr. B. R. Ambedkar Center for ' 'Biomedical Research &amp;Delhi School of Public Health, IoE, ' 'University of Delhi, Delhi, India'}]}], 'member': '301', 'published-online': {'date-parts': [[2024, 1, 4]]}, 'reference': [ { 'key': 'e_1_3_5_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/978-1-4939-9752-7_15'}, {'key': 'e_1_3_5_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acsinfecdis.1c00070'}, {'key': 'e_1_3_5_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40262-019-00806-9'}, {'key': 'e_1_3_5_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/v12050497'}, {'key': 'e_1_3_5_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fddsv.2022.898035'}, {'key': 'e_1_3_5_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1155/2021/1828792'}, {'key': 'e_1_3_5_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/mBio.02451-20'}, {'key': 'e_1_3_5_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1063/1.464397'}, {'key': 'e_1_3_5_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1063/1.470117'}, {'key': 'e_1_3_5_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1517/13543784.12.8.1413'}, { 'key': 'e_1_3_5_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acs.jpclett.0c03119'}, {'key': 'e_1_3_5_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/jac/dkaa474'}, {'key': 'e_1_3_5_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/bib/bbab111'}, { 'key': 'e_1_3_5_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1634/theoncologist.6-4-363'}, {'key': 'e_1_3_5_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/srep32153'}, { 'key': 'e_1_3_5_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H'}, {'key': 'e_1_3_5_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/ct700301q'}, { 'key': 'e_1_3_5_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2006.04.014'}, { 'key': 'e_1_3_5_20_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/07391102.2022.2079561'}, {'key': 'e_1_3_5_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-021-03819-2'}, { 'key': 'e_1_3_5_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/07391102.2022.2121943'}, { 'key': 'e_1_3_5_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.chembiol.2004.07.013'}, {'key': 'e_1_3_5_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s42003-021-01736-8'}, {'key': 'e_1_3_5_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/protein/gzw025'}, { 'key': 'e_1_3_5_26_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acs.biochem.7b01073'}, {'key': 'e_1_3_5_27_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/prot.25900'}, { 'key': 'e_1_3_5_28_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/bioinformatics/btab666'}, {'key': 'e_1_3_5_29_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/ar000033j'}, {'key': 'e_1_3_5_30_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/mnfr.201200227'}, {'key': 'e_1_3_5_31_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.00409-12'}, {'key': 'e_1_3_5_32_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-020-2180-5'}, {'key': 'e_1_3_5_33_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fmolb.2021.678701'}, {'key': 'e_1_3_5_34_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.1116480'}, { 'key': 'e_1_3_5_35_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/07391102.2020.1805019'}, { 'key': 'e_1_3_5_36_1', 'unstructured': 'Loxistatin Acid (E-64C) (n.d.). 99.82%(HPLC) selleck cysteine protease ' 'inhibitor.”. Selleckchem.Com. Accessed May 2 2023. ' 'https://www.selleckchem.com/products/loxistatin-acid-e-64c.html.'}, {'key': 'e_1_3_5_37_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11030-022-10490-w'}, {'key': 'e_1_3_5_38_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/nar/gkab321'}, { 'key': 'e_1_3_5_39_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acs.jmedchem.7b01337'}, { 'key': 'e_1_3_5_40_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.slasd.2021.10.012'}, {'key': 'e_1_3_5_41_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/0091270007304103'}, {'key': 'e_1_3_5_42_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/nar/gkz367'}, { 'key': 'e_1_3_5_43_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.micpath.2023.105994'}, {'key': 'e_1_3_5_44_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.fmre.2022.01.034'}, { 'key': 'e_1_3_5_45_1', 'unstructured': 'PubChem. n.d. (2023). Miltefosine . Accessed May 2. ' 'https://pubchem.ncbi.nlm.nih.gov/compound/3599.'}, {'key': 'e_1_3_5_46_1', 'doi-asserted-by': 'publisher', 'DOI': '10.26434/chemrxiv.13377119'}, {'key': 'e_1_3_5_47_1', 'doi-asserted-by': 'publisher', 'DOI': '10.17616/R3Q59F'}, {'key': 'e_1_3_5_48_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-020-2577-1'}, { 'key': 'e_1_3_5_49_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0040521'}, { 'key': 'e_1_3_5_50_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.ppat.1008392'}, {'key': 'e_1_3_5_51_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-020-2179-y'}, { 'key': 'e_1_3_5_52_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bbapap.2015.10.004'}, { 'key': 'e_1_3_5_53_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.ppat.1007236'}, {'key': 'e_1_3_5_54_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.sbi.2013.11.005'}, {'key': 'e_1_3_5_55_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.1241475'}, { 'key': 'e_1_3_5_56_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/bs.aivir.2019.08.002'}, {'key': 'e_1_3_5_57_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s12038-020-00102-w'}, {'key': 'e_1_3_5_58_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jcc.20291'}, {'key': 'e_1_3_5_59_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2020.02.058'}, {'key': 'e_1_3_5_60_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41401-021-00735-z'}, { 'key': 'e_1_3_5_61_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.50.2.414-421.2006'}, {'key': 'e_1_3_5_62_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.abb2762'}, {'key': 'e_1_3_5_63_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.1914677117'}, {'key': 'e_1_3_5_64_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nmeth.3213'}, { 'key': 'e_1_3_5_65_1', 'doi-asserted-by': 'publisher', 'DOI': '10.5555/cmj.0366-6999.118.06.p493.01'}, {'key': 'e_1_3_5_66_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nature08675'}, { 'key': 'e_1_3_5_67_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41392-021-00558-8'}], 'container-title': 'Journal of Biomolecular Structure and Dynamics', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.tandfonline.com/doi/pdf/10.1080/07391102.2023.2300060', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 1, 4]], 'date-time': '2024-01-04T09:48:39Z', 'timestamp': 1704361719000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.tandfonline.com/doi/full/10.1080/07391102.2023.2300060'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 1, 4]]}, 'references-count': 66, 'alternative-id': ['10.1080/07391102.2023.2300060'], 'URL': 'http://dx.doi.org/10.1080/07391102.2023.2300060', 'relation': {}, 'ISSN': ['0739-1102', '1538-0254'], 'subject': ['Molecular Biology', 'General Medicine', 'Structural Biology'], 'container-title-short': 'Journal of Biomolecular Structure and Dynamics', 'published': {'date-parts': [[2024, 1, 4]]}, 'assertion': [ { 'value': 'The publishing and review policy for this title is described in its Aims & ' 'Scope.', 'order': 1, 'name': 'peerreview_statement', 'label': 'Peer Review Statement'}, { 'value': 'http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=tbsd20', 'URL': 'http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=tbsd20', 'order': 2, 'name': 'aims_and_scope_url', 'label': 'Aim & Scope'}, { 'value': '2023-07-15', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-12-13', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2024-01-04', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0